ArticleInternational journal of clinical and experimental medicine2015
Association between RAD51 polymorphism and breast cancer susceptibility: a meta analysis.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 6 citations in OpenAlex.
- Clinical and genetic characterization of hereditary breast cancer in a Chinese population.Hereditary cancer in clinical practice · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRAD51 interacting with BRCA1 and BRCA2 could modulate the penetrance of BRCA1/BRCA2 mutations, which may increase susceptibility for breast cancer by inhibiting DNA repair and genome stability. The purpose of this study was to provide refined statistical evidence for the association between RAD51 polymorphism and breast cancer risk. DESIGN AND
resultsWe conducted a meta-analysis of 15 publications with a total of 11,766 cancer cases and 11,227 controls. We summarized the data on the association of RAD51 polymorphism with breast cancer risk and performed subgroup analyses by ethnicity and control source. The pooled ORs based on fixed-effects model did not indicate a modified risk of breast cancer associated with RAD51 polymorphism in the overall population. Nor did we find a significant association in any stratified analysis.
conclusionsThis meta-analysis suggested that RAD51 polymorphism did not appear to represent a significant risk factor for breast cancer.
Indexed as
Identifiers
25932169PMC4402816W364138641What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.